FORT WAYNE, Ind. — A recent analysis published in Clinical Nutrition has identified fifteen reported instances of Wernicke encephalopathy, a rare but potentially life‑threatening neurological disorder caused by severe thiamine (vitamin B1) deficiency, in individuals taking GLP‑1 receptor agonists for weight loss or diabetes management.
What the study found
The researchers examined reports from the FDA’s Adverse Event Reporting System, previously published medical literature, and records from their own medical center. The medications involved were semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). While the analysis cannot prove a direct cause‑and‑effect relationship, it highlights a pattern worth attention.
Why the deficiency occurs
GLP‑1 drugs are known to suppress appetite and can cause nausea, vomiting, and rapid weight loss in some patients. When a person eats very little for an extended period—especially while losing nutrients through vomiting—the body may become severely deficient in thiamine. This deficiency can impair normal brain function and, in extreme cases, lead to Wernicke encephalopathy.
Symptoms of the disorder include confusion, loss of balance or coordination, and vision changes. Without prompt treatment, the condition can cause permanent neurological damage or be fatal.
Expert perspective
Karthik Achari, a Chicago‑based clinician not involved in the research, emphasized that the fifteen cases represent a tiny fraction of the millions of people using GLP‑1 medications. “That’s out of millions of people on these medications. So this is rare,” he told Fox News Digital. “But it’s real, it’s serious, and the mechanism makes sense.”
Achari warned that the appetite‑suppressing effects of GLP‑1 drugs do not reduce the body’s nutritional requirements. Patients must still obtain adequate protein, vitamins, fluids, and other nutrients even when they feel less hungry.
Who may be at higher risk
The study and experts note that individuals with a history of bariatric surgery or those who consume alcohol heavily may face an elevated risk of thiamine deficiency. Persistent vomiting or severe gastrointestinal upset should prompt medical evaluation, especially if accompanied by rapid weight loss.
Nutritionist Erin Palinski‑Wade added that patients should not dismiss severe or prolonged symptoms as merely typical side effects. “Don’t assume every side effect is just part of being on a GLP‑1,” she said. “Severe or persistent symptoms deserve attention.”
What patients should do
Healthcare providers advise anyone on a GLP‑1 medication who experiences persistent vomiting, difficulty eating or drinking, confusion, balance problems, or vision changes to seek professional care promptly. Discussing any significant side effects or rapid weight loss with the prescribing clinician is essential.
The researchers stress that the findings do not mean patients should stop their prescribed GLP‑1 therapy without medical guidance. Instead, they serve as a reminder that reduced appetite can have nutritional consequences, and proactive monitoring of food and fluid intake is crucial.
Looking ahead
Further research is needed to clarify the relationship between GLP‑1 drugs, nutritional deficiencies, and Wernicke encephalopathy. In the meantime, clinicians and patients alike are encouraged to remain vigilant about nutrition while using these powerful weight‑loss and diabetes medications.
Original reporting: WOWO News/Talk (Fort Wayne) — read the source article.
